Bliss GVS Pharma Limited (BLISSGVS.NS)
INR 126.38
(1.36%)
INR 126.38
(1.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.1 Billion INR | -11.92% |
| 2022 | 2.39 Billion INR | -8.71% |
| 2021 | 2.62 Billion INR | 5.39% |
| 2020 | 2.48 Billion INR | -10.69% |
| 2019 | 2.78 Billion INR | 13.73% |
| 2018 | 2.45 Billion INR | -21.55% |
| 2017 | 3.12 Billion INR | -28.69% |
| 2016 | 4.37 Billion INR | 38.58% |
| 2015 | 3.16 Billion INR | 1.89% |
| 2014 | 3.1 Billion INR | 8.56% |
| 2013 | 2.85 Billion INR | -8.8% |
| 2012 | 3.13 Billion INR | 216.21% |
| 2011 | 990.86 Million INR | 111.39% |
| 2010 | 468.73 Million INR | 81.64% |
| 2009 | 258.05 Million INR | -12.16% |
| 2008 | 293.77 Million INR | 1.69% |
| 2007 | 288.89 Million INR | -15.16% |
| 2006 | 340.53 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.34 Billion INR | 123.38% |
| 2024 Q1 | -10.02 Billion INR | -575.61% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 2.1 Billion INR | -11.92% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 2.34 Billion INR | 0.0% |
| 2023 Q4 | 2.1 Billion INR | 0.0% |
| 2022 FY | 2.39 Billion INR | -8.71% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 2.15 Billion INR | 0.0% |
| 2022 Q4 | 2.39 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q4 | 2.62 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 2.84 Billion INR | 0.0% |
| 2021 FY | 2.62 Billion INR | 5.39% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 2.48 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 2.48 Billion INR | -10.69% |
| 2020 Q2 | 2.96 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 2.62 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 2.78 Billion INR | 13.73% |
| 2019 Q4 | 2.78 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 2.45 Billion INR | -21.55% |
| 2018 Q4 | 2.45 Billion INR | 0.0% |
| 2018 Q2 | 2.46 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 5.25 Billion INR | 0.0% |
| 2017 FY | 3.12 Billion INR | -28.69% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 3.12 Billion INR | 0.0% |
| 2016 FY | 4.37 Billion INR | 38.58% |
| 2016 Q4 | 4.37 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 2.79 Billion INR | 0.0% |
| 2015 Q4 | 3.16 Billion INR | 0.0% |
| 2015 FY | 3.16 Billion INR | 1.89% |
| 2014 FY | 3.1 Billion INR | 8.56% |
| 2013 FY | 2.85 Billion INR | -8.8% |
| 2012 FY | 3.13 Billion INR | 216.21% |
| 2012 Q4 | 3.13 Billion INR | 0.0% |
| 2012 Q2 | 3.28 Billion INR | 0.0% |
| 2011 FY | 990.86 Million INR | 111.39% |
| 2010 FY | 468.73 Million INR | 81.64% |
| 2009 FY | 258.05 Million INR | -12.16% |
| 2008 FY | 293.77 Million INR | 1.69% |
| 2007 FY | 288.89 Million INR | -15.16% |
| 2006 FY | 340.53 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Hikal Limited | 12.99 Billion INR | 83.772% |
| Morepen Laboratories Limited | 4.45 Billion INR | 52.714% |
| Innova Captab Limited | 4.89 Billion INR | 56.961% |
| Albert David Limited | 1.15 Billion INR | -83.362% |
| Alembic Limited | 1.43 Billion INR | -47.256% |
| Alkem Laboratories Limited | 48.6 Billion INR | 95.661% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 87.041% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -223.305% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 56.676% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -630.214% |
| Brooks Laboratories Limited | 248.6 Million INR | -748.287% |
| Eris Lifesciences Limited | 38.26 Billion INR | 94.489% |
| FDC Limited | 3.7 Billion INR | 43.146% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 59.296% |
| Gufic Biosciences Limited | 5.59 Billion INR | 62.341% |
| Hester Biosciences Limited | 3.59 Billion INR | 41.335% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 7.889% |
| Ind-Swift Limited | 13.45 Billion INR | 84.324% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 66.679% |
| Ipca Laboratories Limited | 33.74 Billion INR | 93.75% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -610.625% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 96.558% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -227.521% |
| Laurus Labs Limited | 42.71 Billion INR | 95.063% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -96.255% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -6.706% |
| Medico Remedies Limited | 438.24 Million INR | -381.205% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 81.201% |
| RPG Life Sciences Limited | 1.38 Billion INR | -52.793% |
| Sigachi Industries Limited | 2.53 Billion INR | 16.688% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 85.035% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.851% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -3.668% |
| Themis Medicare Limited | 1.88 Billion INR | -11.727% |
| Unichem Laboratories Limited | 8.06 Billion INR | 73.866% |
| Vaishali Pharma Limited | 371.16 Million INR | -468.174% |
| Venus Remedies Limited | 1.39 Billion INR | -51.411% |
| Windlas Biotech Limited | 1.76 Billion INR | -19.638% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1.35% |
| Orchid Pharma Limited | 3.84 Billion INR | 45.14% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 17.662% |
| Wanbury Limited | 3.15 Billion INR | 33.169% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 74.44% |
| Aarti Drugs Limited | 11.5 Billion INR | 81.669% |
| Lupin Limited | 96.23 Billion INR | 97.809% |
| Sakar Healthcare Limited | 1.26 Billion INR | -66.935% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.614% |
| Divi's Laboratories Limited | 18.99 Billion INR | 88.895% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 42.399% |
| Mankind Pharma Limited | 23.87 Billion INR | 91.167% |
| Sequent Scientific Limited | 8.27 Billion INR | 74.513% |
| Neuland Laboratories Limited | 5.49 Billion INR | 61.647% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 80.306% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.761% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 97.063% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -169.046% |
| Wockhardt Limited | 39.87 Billion INR | 94.711% |
| Bal Pharma Limited | 2.51 Billion INR | 16.025% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.029% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -1219.756% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 39.843% |
| Shilpa Medicare Limited | 12.93 Billion INR | 83.693% |
| Valiant Laboratories Limited | 1.05 Billion INR | -99.275% |
| Ajanta Pharma Limited | 10.71 Billion INR | 80.31% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -22.452% |
| Granules India Limited | 22.95 Billion INR | 90.813% |
| Medicamen Biotech Limited | 940.36 Million INR | -124.258% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -80.984% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.624% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.43% |
| NATCO Pharma Limited | 10.53 Billion INR | 79.977% |
| Suven Life Sciences Limited | 148.62 Million INR | -1318.946% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 29.088% |
| Strides Pharma Science Limited | 37.68 Billion INR | 94.403% |
| Indoco Remedies Limited | 10.34 Billion INR | 79.609% |
| Alpa Laboratories Limited | 307.12 Million INR | -586.649% |
| Lasa Supergenerics Limited | 541.92 Million INR | -289.141% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 45.828% |